Analysis of the key themes driving M&A activity reveals that COVID-19 accounted for 7 pharmaceutical deals announced in Q2 2023, worth a total value of $1.8bn. The $1.7bn acquisition of CTI BioPharma by Cleopatra Acquisition was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q2 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In volume terms, COVID-19-related deal activity increased by 75% in Q2 2023 versus the previous quarter and was 250% higher than in Q2 2022.
The top-ranked financial advisors supporting these M&A deals in Q2 2023 were Computershare; Ernst & Young Global; MTS Health Partners with 1, 1, 1 deals respectively.
The top-ranked legal advisors supporting these M&A deals in Q2 2023 were Gibson, Dunn & Crutcher; Latham & Watkins; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo PC with 1, 1, 1 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q2 2023 – Thematic Intelligence, buy the report here.